Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
13 Nov 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/korro-lays-34-staff-lead-drug-disappoints-and-novo-nordisk-pauses-pact
12 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/12/3186799/0/en/Korro-Reports-Third-Quarter-Financial-Results-Provides-Updates-on-KRRO-110-in-Alpha-1-Antitrypsin-Deficiency-and-Additional-Pipeline-Programs.html
02 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/02/3143181/0/en/Korro-to-Participate-in-Upcoming-Investor-and-Scientific-Conferences.html
12 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/12/3131541/0/en/Korro-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html
21 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/21/3118672/0/en/Korro-Receives-European-Medicines-Agency-Orphan-Drug-Designation-for-KRRO-110.html
14 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/14/3081589/0/en/Korro-to-Participate-in-Upcoming-Investor-Conferences.html
Drugs in Development
Details:
KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2025
Lead Product(s) : KRRO-110
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Details : KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 14, 2025
Details:
KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2025
Lead Product(s) : KRRO-110
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Korro Bio Doses First Patients in REWRITE Phase 1/2a Study for AAT Deficiency
Details : KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 13, 2025
Details:
KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2024
Lead Product(s) : KRRO-110
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Korro Receives Australian Approval for Phase 1/2a REWRITE Study of KRRO-110
Details : KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 21, 2024
Details:
KRRO-110 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of alpha 1-Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 06, 2024
Lead Product(s) : KRRO-110
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
Details : KRRO-110 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of alpha 1-Antitrypsin Deficiency.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 06, 2024
Details:
KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2024
Lead Product(s) : KRRO-110
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Korro Submits Regulatory Filing for KRRO-110 First-In-Human Study
Details : KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 04, 2024
Details:
The collaboration brings together Novo's deep cardiometabolic disease understanding and drug development experience with Korro’s platform to develop RNA editing product candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: Novo Nordisk
Deal Size: $530.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Novo Nordisk
Deal Size : $530.0 million
Deal Type : Collaboration
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
Details : The collaboration brings together Novo's deep cardiometabolic disease understanding and drug development experience with Korro’s platform to develop RNA editing product candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 16, 2024
Details:
The net proceeds will be used to support the clinical advancement of Korro's lead product KRRO-110 for treating patients suffering from alpha-1 antitrypsin deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Oligonucleotide
Sponsor: Deep Track Capital
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 18, 2024
Lead Product(s) : KRRO-110
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Deep Track Capital
Deal Size : $70.0 million
Deal Type : Private Placement
Korro Announces $70 Million Private Placement
Details : The net proceeds will be used to support the clinical advancement of Korro's lead product KRRO-110 for treating patients suffering from alpha-1 antitrypsin deficiency.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 18, 2024
Details:
KRRO-110 is based on Korro’s proprietary RNA editing platform, OPERA™. It is being evaluated in preclinical studies for the treatment of Alpha-1 Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 18, 2024
Lead Product(s) : KRRO-110
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Korro Highlights Data for AAT and RNA Editing Program Progress
Details : KRRO-110 is based on Korro’s proprietary RNA editing platform, OPERA™. It is being evaluated in preclinical studies for the treatment of Alpha-1 Antitrypsin Deficiency.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 18, 2024
Details:
KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Lead Product(s): KRRO-110
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Oligonucleotide
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 07, 2023
Lead Product(s) : KRRO-110
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 07, 2023
Details:
The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs including, OPERA platform which harnesses the body’s natural base editing system, specifically ADAR, to make targeted edits to a single RNA base.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Recipient: Frequency Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Recipient : Frequency Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Details : The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs including, OPERA platform which harnesses the body’s natural base editing system, specifically ADAR, to make targeted edits to a single RNA base.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
